The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Anti-PEG IgM production as a function of time interval was tested in sera of rats intravenously injected with PEGylated liposomal gambogenic acid (PEG-GEA-L) at 1.500 mg/kg (a) [57]. Mice were treated with PEGylated liposomes of 1 μmol/kg, and the production of anti-PEG IgM in mouse sera was determined as a function of time (b) [58]. The effect of PEG-GEA-L doses on anti-PEG IgM production was recorded on the fifth day after the first injection. Rats were treated with low (1.125 mg/kg), medium (1.500 mg/kg), and high (1.875 mg/kg) dosages. ELISA was utilized to determine anti-PEG IgM (c). Anti-PEG IgM in organ tissues of rats that were intravenously injected with various PEG-GEA-L doses (d). Used with permission from [57]. (* p < 0.05, ** p < 0.01).](https://figures.cochat.ai/paper-figures/7f992d6c8db34717873a1a30c4da9e3e/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-3.jpg)
![Figure 4 Production of anti-PEG IgM in the serum of mice injected PEGylated liposomes (PL) with various functional groups were determined by ELISA on the fifth day after administration. The lowest immunogenicity was exhibited by PL–OH (a). C3 binding in the serum of mice injected P–OCH3 and PL–OH on the fifth day, with non-treated mice as the control sample. Sera were diluted with a gelatin veronal buffer with Mg++ and Ca++ (GVB++) buffer (b) and an Mg2+/ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) buffer (c). Mice treated with PL–OH demonstrated the highest compliment activation, driving the ABC phenomenon (d). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65]. Production of anti-PEG IgM rat sera against PEGylated emulsions (DE) with various functional groups seven days post-administration (e). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [66]. (* p < 0.05, ** p < 0.01, *** p < 0.001).](https://figures.cochat.ai/paper-figures/334fab17dd8d42068469652d228b7ccc/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-4.jpg)



![Figure 8 Chemical structure of the zwitterionic carboxybetaine functionalized polypeptide (PepCB) [79] (a). The preparation of poly(2-methacryloyloxyethyl phosphorylcholine)/poly(β-amino ester) (PMPC/PAE) mixed shell micelles (MSMs) with pH-sensitive behavior: MSMs were in zwitterionic state at a physiological blood pH (7.4) and in a cationic form within the tumor microenvironment (pH 6.5) (b).](https://figures.cochat.ai/paper-figures/52e563c21690478d8f338572002a504f/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these chemical modifications can potentially decrease transduction efficiency, lower production yield, alter biodistribution of AAV vectors, and result in anti-polymer antibody formation [198, 199].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 3×
“However, the repeated administration of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76].”
BackgroundPEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Jiang, S., & Cao, Z. (2010) · Advanced Materials · doi:10.1002/adma.200901407 · Cited by 2,027 · cited 4×
“Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB) (Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].”
BackgroundInfluentialChemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 3×
“When considering continuously increasing PEG density, it was shown that high PEG densities did not significantly impact NP clearance from circulation [59], though discussion of the relationship between clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37].”
Background
Research works printed but not linked: 4
- 23. Mukhopadhyay S. Nano drugs: A critical review of their patents and market. In: Mohapatra S.S., Ranjan S., Dasgupta N., Mishra R.K., Thomas S., editors. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Elsevier Ltd.; Amsterdam, The Netherlands: 2019. pp. 523–551.
- 39. Elsadek N.E., Abu Lila A.S., Ishida T. 5-Immunological responses to PEGylated proteins: Anti-PEG antibodies. In: Pasut G., Zalipsky S., editors. Polymer-Protein Conjugates. Elsevier; Amsterdam, The Netherlands: 2020. pp. 103–123.
- 47. Seppälä J.T.S., Mäkelä O. Hapten. In: Roitt I., Delves P., editors. Encyclopedia of Immunology. 2nd ed. Elsevier Ltd.; Amsterdam, The Netherlands: 1998. pp. 1050–1052.
- 72. Abbina S., Parambath A. PEGylation and its alternatives: A summary. In: Parambath A., editor. Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol. Elsevier Ltd.; Amsterdam, The Netherlands: 2018. pp. 363–376.
Cited by
Items 201–300 of 669
Pandey, P. K., Arya, D. K., Kumar, A., Kaushik, A. K., Mishra, Y. K., & Rajinikanth, P. S. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb02570a · Cited by 29
Christensen, J. K., Colletti, N. J., Hooshfar, S., Jiang, R., Kuo, C., Lindmark, B., Lumen, A., Youssef, A. S., Albertolle, M. E., Aluri, K. C., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf778 · Cited by 31
“Bioconjugation with a polymer like polyethylene glycol (PEG) is a common strategy to enhance oligonucleotide PK by increasing solubility and preventing rapid elimination [ 4 ].”
PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation
Gao, P. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.133 · Cited by 34
Mehrabi, F., Shamspur, T., Sheibani, H., Mostafavi, A., Mohamadi, M., Hakimi, H., Bahramabadi, R., & Salari, E. (2021) · BioMetals · doi:10.1007/s10534-021-00338-5 · Cited by 28
Fluorinated PEG-PEI Coated Magnetic Nanoparticles for siRNA Delivery and CXCR4 Knockdown
Cao, Y., Zhang, S., Ma, M., & Zhang, Y. (2022) · Nanomaterials · doi:10.3390/nano12101692 · Cited by 28
“Polyethylene glycol (PEG) has the advantages of good aqueous solubility and high biocompatibility, which makes it suitable for biomedical applications [22].”
BackgroundNaimi, N., Seyedmirzaei, H., Hassannejad, Z., & Khaboushan, A. S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116691 · Cited by 29
Gopinath, G., Shanmugaraj, P., Sasikumar, M., Shadap, M., Banu, A., & Ayyasamy, S. (2023) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2023.100498 · Cited by 30
Recent advances on drug delivery nanocarriers for cerebral disorders
Zhou, Z., Sun, T., & Jiang, C. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abdc97 · Cited by 29
Huang, R., Luther, D. C., Zhang, X., Gupta, A., Tufts, S. A., & Rotello, V. M. (2021) · Nanomaterials · doi:10.3390/nano11041001 · Cited by 29
Chan, Y., Ng, S. W., Singh, S. K., Gulati, M., Gupta, G., Chaudhary, S. K., Hing, G. B., Collet, T., MacLoughlin, R. J., Löbenberg, R., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119744 · Cited by 27
Polymeric Nanostructures Containing Proteins and Peptides for Pharmaceutical Applications
Vardaxi, A., Kafetzi, M., & Pispas, S. (2022) · Polymers · doi:10.3390/polym14040777 · Cited by 30
Jacob, P. L., Brugnoli, B., Giudice, A. D., Phan, H., Chauhan, V. M., Beckett, L., Gillis, R. B., Moloney, C., Cavanagh, R. J., Krumins, E., et al. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.03.124 · Cited by 30
Sui, D., Wang, Y., Sun, W., Wei, L., Li, C., Gui, Y., Qi, Z., Liu, X., Song, Y., & Deng, Y. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c02762 · Cited by 28
Pavón, C., Benetti, E. M., & Lorandi, F. (2024) · Langmuir · doi:10.1021/acs.langmuir.4c00956 · Cited by 32
The evolving landscape of gene therapy strategies for the treatment of osteoarthritis
Grol, M. W. (2024) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2023.12.009 · Cited by 29
Gerasimovich, E. S., Karaulov, A. V., Nabiev, I. R., & Sukhanova, A. V. (2025) · Nanomaterials · doi:10.3390/nano15131013 · Cited by 32
Dogan, N. O., Bozuyuk, U., Erkoc, P., Karacakol, A. C., Cingöz, A., Seker-Polat, F., Nazeer, M. A., Sitti, M., Onder, T. B., & Kızılel, S. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100033 · Cited by 27
Chang, T.-C., Chen, B., Wu, J.-Y., Cheng, T., & Roffler, S. R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112502 · Cited by 27
Challenges for the Development of Extracellular Vesicle-Based Nucleic Acid Medicines
Kuriyama, N., Yoshioka, Y., Kikuchi, S., Okamura, A., Azuma, N., & Ochiya, T. (2021) · Cancers · doi:10.3390/cancers13236137 · Cited by 29
Conte, M., & Cauda, V. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200079 · Cited by 29
Nguyen, D. H., Vo, T. N. N., Le, N. T. T., Thi, D. P. N., & Thi, T. T. H. (2020) · Green Processing and Synthesis · doi:10.1515/gps-2020-0044 · Cited by 31
Self-citationNiclot, F. B., Montalbano, G., Fiorilli, S., & Vitale‐Brovarone, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041718 · Cited by 27
“effect on the surface charge of DDSs [65].”
BackgroundInfluentialEmerging delivery strategy for oncolytic virotherapy
Zhu, J., Ma, J., Huang, M., Deng, H., & Shi, G. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200809 · Cited by 35
“34,35 Utilizing a cationic polymer as a carrier and complexing with OVs through electrostatic interaction can improve the virus ’ s transduction rate to some extent.”
BackgroundGonçalves, J., & Caliceti, P. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s481420 · Cited by 30
Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases
Razavi, R., Kegel, M., Muscat-Rivera, J., Weissman, D., & Melamed, J. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101566 · Cited by 32
“116 Potential candidates have emerged, including polysarcosines, 117–120 polyoxazolines, 121,122 poly(N-vinyl-pyrrolidone), 123 and poly(N-methyl-N-vinylacetamide).”
Zhang, Y., Hu, M., Xin, R., Xu, X., Zhang, Z., Peng, H., Cai, R., Chen, C., Whittaker, A. K., & Fu, C. (2025) · Polymer science & technology. · doi:10.1021/polymscitech.5c00084 · Cited by 25
Prakash, S., Kumbhojkar, N., Clegg, J. R., & Mitragotri, S. (2020) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2020.101408 · Cited by 28
Abad-Álvaro, I., Leite, D., Bartczak, D., Cuello-Núñez, S., Gómez-Gómez, B., Madrid, Y., Aramendía, M., Resano, M., & Infante, H. G. (2021) · Journal of Analytical Atomic Spectrometry · doi:10.1039/d1ja00068c · Cited by 25
Sustainability in Heritage Wood Conservation: Challenges and Directions for Future Research
Walsh, Z. (2021) · Forests · doi:10.3390/f13010018 · Cited by 29
Vardaxi, A., & Pispas, S. (2023) · Polymers · doi:10.3390/polym15061519 · Cited by 27
“POEGMA is a non-ionic oligomer with a hydrophilic profile.”
MethodInfluentialDomingo-Diez, J., Souiade, L., Marta, S., Manzaneda‐González, V., Guerrero‐Martínez, A., Breton, L. M., Isidoro, M. R., Ramírez‐Castillejo, C., Serrano Olmedo, J. J., & Ramos, M. (2023) · Congreso Anual de la Sociedad Española de Ingeniería Biomédica (CASEIB) · doi:10.31428/10317/13474 · Cited by 27
Engineering Synthetic Erythrocytes as Next‐Generation Blood Substitutes
Gomes, F. L., Jeong, S., Shin, S. R., Leijten, J., & Jonkheijm, P. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202315879 · Cited by 27
Babaei, M., Abrishami, A., Iranpour, S., Saljooghi, A. S., & Matin, M. M. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01707-6 · Cited by 25
“Generally, PEGylation serves as an accepted method for enhancing the biocompatibility of nanoparticles by increasing their half-life in the blood for efficient drug and gene delivery to target cells and tissues [81–83]. data are in agreement with the FT-IR data reported by Su and colleagues.”
Najer, A., Belessiotis‐Richards, A., Kim, H., Saunders, C., Fenaroli, F., Adrianus, C., Che, J., Tonkin, R. L., Høgset, H., Lörcher, S. L., et al. (2022) · Small · doi:10.1002/smll.202201993 · Cited by 26
Sun, S., Angelis, G. D., Bertella, S., Jones, M. J., Dick, G. R., Amstad, E., & Luterbacher, J. S. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202312823 · Cited by 26
Progress in oncolytic viruses modified with nanomaterials for intravenous application
Chen, L., Ma, Z., Chen, X., Xie, Y., Ouyang, D., Song, S., Zhao, X., & Liu, F. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0275 · Cited by 31
“PEG PEG, a hydrophilic linear polymer, has biocompatible and nonimmunogenic characteristics 78 .”
BackgroundMorbidelli, M., Papini, E., & Tavano, R. (2024) · Frontiers in Nanotechnology · doi:10.3389/fnano.2024.1500567 · Cited by 24
Bioinspired Nanoplatforms: Polydopamine and Exosomes for Targeted Antimicrobial Therapy
Barathan, M., & Hanafiah, A. (2025) · Polymers · doi:10.3390/polym17121670 · Cited by 24
Harini, A., & Ilaiyaraja, P. (2025) · RSC Advances · doi:10.1039/d5ra01788b · Cited by 24
Polymers for Improved Delivery of Iodinated Contrast Agents
Zhang, J., Liu, W., Zhang, P., Song, Y., Ye, Z., Fu, H., Yang, S., Qin, Q., Guo, Z., & Zhang, J. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01082 · Cited by 26
New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy
Theyab, A., Alsharif, K. F., Alzahrani, K. J., Oyouni, A. A. A., Hawsawi, Y. M., Algahtani, M., Alghamdi, S. A., & Alshammary, A. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1026377 · Cited by 24
Contrasting Properties of Polymeric Nanocarriers for MRI-Guided Drug Delivery
Łopuszyńska, N., & Węglarz, W. P. (2023) · Nanomaterials · doi:10.3390/nano13152163 · Cited by 26
Polymer mediated light responsive therapeutics delivery system to treat cancer
Kapoor, D. U., Maheshwari, N., Bag, A., Sharma, D. M. C., Prajapati, B. G., & Maheshwari, R. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.112923 · Cited by 24
Jiao, J., Jiao, X., Wang, C., Wei, L., Wang, G.-F., Deng, Y., & Song, Y. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01838-2 · Cited by 22
“PEG, the unique properties of PEG in the field of pharmaceutical preparations are still beyond the reach of other materials (9,10).”
BackgroundChoi, Y. S., Cho, H., Choi, W.-G., Lee, S. S., Huh, K. M., Shim, M. S., Park, I. S., Cho, Y., Lee, J. Y., Lee, H. S., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121307 · Cited by 22
Self-citationCruz-Nova, P., Ancira-Cortez, A., Ferro‐Flores, G., Ocampo‐García, B., & Gibbens-Bandala, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051095 · Cited by 22
Lipid‐based nucleic acid therapeutics with in vivo efficacy
Sufian, M. A., & Ilies, M. A. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1856 · Cited by 26
Song, R., Dong, Y., Zhong, Z., Zhao, Q., Hu, Y., Lei, M., Lei, P., Jiang, Z., Qian, K., Shi, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00601 · Cited by 22
Thi, T. T. H., Luu, C. H., Kim, J. H., Leach, J. K., & Park, K. D. (2025) · Burns & Trauma · doi:10.1093/burnst/tkaf051 · Cited by 24
“These polymers can be derived from both natural and synthetic sources, and their structures and properties have been extensively detailed in numerous comprehensive reviews [14–16 , 28– 30].”
Self-citationEnzymes and biopolymers. The opportunity for the smart design of molecular delivery systems
Berti, I. R., Islan, G. A., & Castro, G. R. (2020) · Bioresource Technology · doi:10.1016/j.biortech.2020.124546 · Cited by 21
Panchani, N. M., Kapadiya, K. M., & Joshi, H. S. (2022) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4543 · Cited by 21
Ansarinik, Z., Kiyani, H., & Yoosefian, M. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.120192 · Cited by 22
Rodrigues, C. F., Fernandes, N. F., de Melo‐Diogo, D., Correia, I. J., & Moreira, A. F. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201214 · Cited by 22
Lv, R., Qian, Z., Zhao, X., Xiong, F., Xu, Y., Fan, W., Yao, X., & Huang, W. H. (2022) · Nano Research · doi:10.1007/s12274-022-5184-7 · Cited by 21
Utilization of superparamagnetic iron oxide nanoparticles (SPIONs) as a vector for drug delivery
Otieno, E., Huang, Y., Li, N., Li, T., Wang, M., Qiu, X., & Xiao, X. (2023) · Applied Nanoscience · doi:10.1007/s13204-023-02853-y · Cited by 21
“…ability to cause hypersensitivity reaction and an immunogenic response that leads into accelerated blood clearance (ABC) phenomenon decreasing the efficacy of drug due to formation of anti-PEG IgM-specific antibodies after repeated administration of PEG(Knop et al. 2010; Hoang et al. 2020).”
BackgroundA review of design criteria for cancer-targeted, nanoparticle-based MRI contrast agents
Rahmati, S., & David, A. E. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102087 · Cited by 24
Nanohybrids as Protein-Polymer Conjugate Multimodal Therapeutics
Kiran, P., Khan, A., Neekhra, S., Pallod, S., & Srivastava, R. (2021) · Frontiers in Medical Technology · doi:10.3389/fmedt.2021.676025 · Cited by 22
Emerging trends of discrete Poly(ethylene glycol) in biomedical applications
Hu, J., & Liu, S. (2022) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2022.100419 · Cited by 28
Kedir, W. M., Li, L., Tan, Y. S., Bajalović, N., & Loke, D. K. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb01667j · Cited by 21
Lachowicz, D., Stroud, J., Hankiewicz, J. H., Gassen, R., Kmita, A., Stępień, J., Celiński, Z., Sikora, M., Żukrowski, J., Gajewska, M., et al. (2022) · Chemistry of Materials · doi:10.1021/acs.chemmater.2c00079 · Cited by 21
Lipid nanoparticle steric stabilization roadmap
Cai, X., Zhai, J., Tran, N. L., Mulet, X., & Drummond, C. J. (2022) · Advances in biomembranes and lipid self-assembly · doi:10.1016/bs.abl.2022.05.003 · Cited by 22
Yan, J., Ji, S., Chang, T., Yu, Z., Zhang, J., Hu, M., Xiu, C., & Huo, Q. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104433 · Cited by 19
Li, Z., Shen, L., Ma, A. L., Talkington, A., Li, Z., Nyborg, A. C., Bowers, M. S., LaMoreaux, B. D., Livingston, E. W., Frank, J. E., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.08.052 · Cited by 20
Jarak, I., Santos, A. I., Pinto, A. H., Domingues, C., da Silva, I. S., Melo, R., Veiga, F., & Figueiras, A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123456 · Cited by 21
Yan, R., Liu, X., Xiong, J., Feng, Q., Xu, J., Wang, H., & Xiao, K. (2020) · RSC Advances · doi:10.1039/d0ra01241f · Cited by 20
Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Garg, Y., Kapoor, D. N., Sharma, A. K., & Bhatia, A. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612828666211222163025 · Cited by 21
Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines
Shiraishi, K. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2538423 · Cited by 24
hadad, A. A. E., Alcudia, A., Begines, B., Perez-Soriano, E. M., & Torres, Y. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101603 · Cited by 24
Gola, A. A., Kozłowska, M., & Musiał, W. (2022) · Polymers · doi:10.3390/polym14214729 · Cited by 19
Mathieu‐Gaedke, M., Böker, A., & Glebe, U. (2023) · Macromolecular Chemistry and Physics · doi:10.1002/macp.202200353 · Cited by 20
Williams, S., Jalal, A. R., Lewis, M. P., & Davies, O. G. (2023) · Journal of Tissue Engineering · doi:10.1177/20417314231155114 · Cited by 21
Majumdar, A. G., Pany, B., Parua, S. S., Mukherjee, D., Panda, A., Mohanty, M., Das, B. B., Si, S., & Mohanty, P. S. (2024) · BioNanoScience · doi:10.1007/s12668-024-01577-9 · Cited by 22
“One of the recent works have reported that improved functionalization of PEG [73] on nanogels significantly decrease their inflammatory responses unlike the unmodified counterpart.”
Kosti, E.-M., Sotiropoulou, H., Tsichlis, I., Tsakiri, M., Naziris, N., & Demetzos, C. (2024) · Materials · doi:10.3390/ma17225454 · Cited by 20
In Vitro and In Vivo Assessment of PEGylated PEI for Anti-IL-8/CxCL-1 siRNA Delivery to the Lungs
Hibbitts, A., Ramsey, J. M., Barlow, J. W., MacLoughlin, R. J., & Cryan, S. (2020) · Nanomaterials · doi:10.3390/nano10071248 · Cited by 20
Hetero‐Diels–Alder Cycloaddition with RAFT Polymers as Bioconjugation Platform
Beloqui, A., Mane, S. R., Langer, M., Glaßner, M., Bauer, D. M., Fruk, L., Barner‐Kowollik, C., & Delaittre, G. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005747 · Cited by 20
Sun, X., Pradeepkumar, P., Rajendran, N. K., Shakila, H., Houreld, N. N., Farraj, D. A. A., Elnahas, Y. M., Elumalai, N., & Rajan, M. (2020) · RSC Advances · doi:10.1039/d0ra03790g · Cited by 19
Pinheiro-Júnior, E. L., Boldrini-França, J., Takeda, A. A. S., Costa, T. R., Peigneur, S., Cardoso, I. A., de Oliveira, I. S., Sampaio, S. V., Fontes, M. R. M., Tytgat, J., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.09.004 · Cited by 20
Ugwu, C. E., Oraeluno, J. N., Eze, K., Ezenma, C. O., & Nwankwo, A. O. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09247 · Cited by 19
“PEGylation has been investigated to improve the stability of some novel drug delivery such as microemulsion, dendrimers, liposomes, micelles, nanoparticles, and so on (Momoh et al., 2020a; Thai et al., 2020).”
BackgroundInulin-g-poly-D,L-lactide, a sustainable amphiphilic copolymer for nano-therapeutics
Sardo, C., Mencherini, T., Tommasino, C., Esposito, T., Russo, P., Gaudio, P. D., & Aquino, R. P. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01135-4 · Cited by 21
Sulfoxide-Containing Polyacrylamides Prepared by PICAR ATRP for Biohybrid Materials
Olszewski, M., Jeong, J., Szczepaniak, G., Li, S., Enciso, A. E., Murata, H., Averick, S. E., Kapil, K., Das, S. R., & Matyjaszewski, K. A. (2022) · ACS Macro Letters · doi:10.1021/acsmacrolett.2c00442 · Cited by 19
Blood Compatibility of Hydrophilic Polyphosphoesters
Pelosi, C., Constantinescu, I., Son, H. H., Tinè, M. R., Kizhakkedathu, J. N., & Wurm, F. R. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01210 · Cited by 20
RAFT step-growth polymerization of bis-acrylamides and their facile degradation
Boeck, P. T., Tanaka, J., You, W., Sumerlin, B. S., & Veige, A. S. (2023) · Polymer Chemistry · doi:10.1039/d3py00379e · Cited by 19
Lysine-Sarcosine PiPo Functionalized Surface with Excellent Hemocompatibility
Hao, K., Cui, R., Fang, L., Ling, J., & Zhu, B. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19677 · Cited by 18
Drug delivery systems for tissue engineering: exploring novel strategies for enhanced regeneration
de Oliveira, J. L., da Silva, M. E. X., Hotza, D., Sayer, C., & Immich, A. P. S. (2024) · Journal of Nanoparticle Research · doi:10.1007/s11051-024-06074-4 · Cited by 19
Aptamer based immunotherapy: a potential solid tumor therapeutic
Mathavan, S., Tam, Y., Mustaffa, K. M. F., & Tye, G. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1536569 · Cited by 21
Tomala, A. M., Słota, D., Florkiewicz, W., Piętak, K., Dyląg, M., & Sobczak‐Kupiec, A. (2022) · Lubricants · doi:10.3390/lubricants10040058 · Cited by 18
Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-α2a
Hauptstein, N., Pouyan, P., Wittwer, K., Cinar, G., Scherf‐Clavel, O., Raschig, M., Licha, K., Lühmann, T. C., Nischang, I., Schubert, U. S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.060 · Cited by 18
Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application
Yan, J., Fei, W., Song, Q., Zhu, Y., Bu, N., Wang, L., Zhao, M., & Zheng, X. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2100010 · Cited by 20
“However, many clinical studies have demonstrated that the appearance of anti-PEG antibodies can result in faster blood clearance, allergies, or even life-threatening complications (Thi et al., 2020).”
BackgroundThe influence of protein corona on liposomal delivery systems: A comprehensive review
Mojarad-Jabali, S., Fatahi, Y., & Dinarvand, R. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107166 · Cited by 20
Tan, X., Li, S., Sheng, R., Zhang, Q., Li, C., Liu, L., Zhang, Y., & Ge, L. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.11.151 · Cited by 17
mRNA therapeutics for disease therapy: principles, delivery, and clinical translation
Zhou, D., Wang, K., Zhang, Y., Ma, K., Yang, X., Li, Z.-Y., Yu, S., Chen, K., & Qiao, S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02782h · Cited by 19
PEGylation, the Glorious Past, Present Dilemma and Future
Lou, C. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v40i.6702 · Cited by 17
Novorolsky, R. J., Kasheke, G. D. S., Hakim, A. M., Földvári, M., Dorighello, G. G., Sekler, I., Vuligonda, V., Sanders, M. E., Renden, R., Wilson, J. J., et al. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1226630 · Cited by 20
Piranaghl, H., Golmohammadzadeh, S., Soheili, V., Sabeti, Z., Memar, B., Jalali, S. M., Taherzadeh, Z., & Bazzaz, B. S. F. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18246 · Cited by 19
“Using PEG as a carrier for bacteriophages can improve their stability, bioavailability, and reduce their immunogenicity [52].”
BackgroundChondroitin Sulphate: An emerging therapeutic multidimensional proteoglycan in colon cancer
Mneimneh, A. T., & Mehanna, M. M. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127672 · Cited by 18
NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines
Sentí, M. E., Ceccaldi, A., Luciani, M., Saber, N., Schürmann, P. J. L., Geerlings, M. W., Hölig, P., de Beer, J., Hannus, M., Campbell, F., et al. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1458636 · Cited by 19
Mazo, A. R., Tran, T. N., Zhang, W., Meng, Y., Reyhani, A., Pascual, S., Fontaine, L., Qiao, G. G., & Piogé, S. (2020) · Polymer Chemistry · doi:10.1039/d0py00838a · Cited by 19
Najer, A., Rifaie‐Graham, O., Yeow, J., Adrianus, C., Chami, M., & Stevens, M. M. (2022) · Macromolecular Bioscience · doi:10.1002/mabi.202200424 · Cited by 19
Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape
Salgado-Pascual, A., Zalba, S., Lasarte, J. J., & Garrido, M. J. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115760 · Cited by 18
Nanoparticles in the fight against antimicrobial challenges: A comprehensive review
Pathak, K., Borthakur, M. S., Sahariah, M., Shankarishan, P., Sahariah, J. J., Deka, S., Das, A., Islam, M. A., Pramanik, P., Borthakur, P. P., et al. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100420 · Cited by 16
Metadata
- Authors
- Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P.
- Affiliations
- Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 758307, Vietnam
- Monash University (AU)
- Graduate University of Science and Technology (VN)
- Yale University (US)
- Ajou University (KR)
- Corresponding author
- Truong, Nghia P.
- ORCID
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2020-02-02
- Volume
- 12
- Issue
- 2
- Pages
- 298
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC7077443
- OpenAlex
- W3003603323
- Cited by
- 668
- References
- 79
- Citations by year
- 2026: 63 · 2025: 106 · 2024: 117 · 2023: 126 · 2022: 118 · 2021: 85 · 2020: 53
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Australian Research Council (DE180100076, DP200100231)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- polyethylene glycol, anti-PEG antibodies, PEGylation, PEG alternatives, drug delivery, bioconjugation, nanomedicine, blood circulation time, hypersensitivity, siRNA, microRNA, oligonucleotides, nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.